NCT04824638View on ClinicalTrials.gov

BNT162b2 Vaccination With 2 Doses in COVID-19 Negative Volunteers and With a Single Dose in COVID-19 Positive Volunteers

PHASE2CompletedINTERVENTIONAL
Enrollment

267

Participants

Timeline

Start Date

March 8, 2021

Primary Completion Date

June 30, 2021

Study Completion Date

December 2, 2023

Conditions
HealthyImmunization; Infection
Interventions
BIOLOGICAL

3 doses of BNT162b2 vaccine

Administration of BNT162 b2 vaccine (30µg in 0.3mL) at D1 D29 and M8, intramuscularly (participants without antecedent of SARS-CoV-2 infection)

BIOLOGICAL

2 dose of BNT162b2 vaccine

Administration of BNT162 b2 vaccine (30µg in 0.3mL) at D1 and M8, intramuscularly (participants with antecedent of SARS-CoV-2 infection)

Trial Locations (11)

14000

Centre de Recherche Clinique, CHU Côte de Nacre, Caen

29609

CIC1412, CHRU Brest, Brest

30029

Service des maladies infectieuses, CHU de Caremeau, Nîmes

37044

CIC1415, CHRU Tours Hôpital Bretonneau, Tours

44093

CIC1413 , Hôtel Dieu - CHU Nantes, Nantes

63000

CIC 1405 , CHU Clermont-Ferrand, Clermont-Ferrand

67091

CIC1434, Nouvel Hôpital Civil - Hôpitaux Universitaires de Strasbourg, Strasbourg

69310

URCI, Hôpital Lyon Sud, Pierre-Bénite

75010

CIC 1427, Hopital Saint-Louis, Paris

94000

CIC1430, Hôpital Henri Mondor, Créteil

75 679

CIC1417, hôpital Cochin, Paris

All Listed Sponsors
collaborator

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

lead

ANRS, Emerging Infectious Diseases

OTHER_GOV

NCT04824638 - BNT162b2 Vaccination With 2 Doses in COVID-19 Negative Volunteers and With a Single Dose in COVID-19 Positive Volunteers | Biotech Hunter | Biotech Hunter